Le Lézard
Classified in: Health
Subjects: STP, FVT

Teens and NIH Scientists Join Forces for 2018 National Drug & Alcohol Facts Week®


WASHINGTON, Jan. 23, 2018 /PRNewswire-USNewswire/ -- Teens and scientists will connect for the eighth annual National Drug & Alcohol Facts Week® (NDAFW) held Jan. 22-28, 2018. This week-long observance gives young people the facts about how alcohol and drugs can affect them, both in the short-term and over their lifetime.  The National Institute on Drug Abuse (NIDA) will be joined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), both part of the National Institutes of Health (NIH), to coordinate the effort.

To view the Digital Media Release, click here.

"National Drug & Alcohol Facts Week® is designed to educate youth regarding the many myths about drug and alcohol use confronting them on a daily basis," said NIDA Deputy Director Dr. Wilson Compton. "By giving teens scientific facts and answering their questions, we're equipping them to make smart decisions."

More than 2,000 NDAFW events across the country and internationally are expected for this January. An interactive map includes brief descriptions of each local event. Event holders are provided with several drug specific online toolkits on how to create an event, publicize it, find an expert, and obtain scientific information on drugs. NIDA will also host its annual National Drugs & Alcohol Chat Day where hundreds of high school students participate in a live online chat with NIH scientists on drug and alcohol use. The chat can be followed online.

Questions from past Chat Days include:

Online resources, including the popular National Drug & Alcohol IQ Challenge, will be interactive and accessible on mobile devices, with videos of scientists answering the IQ Challenge questions to better illustrate the science behind the answers. By taking the quiz, teens can better understand the risks and side effects of drug use. By giving teens the scientific facts about drugs, they can be better prepared to make good decisions for themselves. This is especially important now, given that marijuana and e-cigarettes are more popular than regular tobacco cigarettes among teens, as found in NIDA's recent Monitoring the Future survey.

NIDA is part of the National Institutes of Health, U.S. Department of Health and Human Services, and supports most of the world's research on the health aspects of drug abuse and addiction. The Institute carries out a large variety of programs to inform policy and improve practice. NIDA's media guide can be found at http://www.drugabuse.gov/publications/media-guide/dear-journalist.

SOURCE National Institute on Drug Abuse


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: